Navigation Links
In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research

BLOOMFIELD, N.J., March 26, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that in vivo study results demonstrating the potential of ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research (2007; 27: 299- 308).

Based on the work of Intae Lee, Ph.D., at the University of Pennsylvania, a paper entitled "Antitumor Efficacy of the Cytotoxic RNase, Ranpirnase, on A549 Human Lung Cancer Xenografts of Nude Mice" shows that:

    * ONCONASE significantly inhibited tumor growth of A549 NSCLC cells both

      in vitro and in vivo; apoptosis was significantly induced by ONCONASE in

      a dose-dependent manner


    * Multiple small doses of ONCONASE were more effective than one large

      single dose of ONCONASE for the inhibition of tumor growth in animal

      studies


    * ONCONASE in combination with cisplatin significantly reduced tumor

      growth of A549 cells; in large tumors, including those unsuccessfully

      treated with cisplatin previously, ONCONASE demonstrated inhibition of

      tumor growth

"ONCONASE has important potential clinical uses for the treatment of NSCLC," said Dr. Lee. "We are pleased that the results of our studies have helped to guide the clinical development of ONCONASE for NSCLC."

Kuslima Shogen, Alfacell's chairman and chief executive officer, said, "The publication of this paper in an important peer-reviewed journal is further recognition of the potential of ONCONASE. This data is evidence that ONCONASE has the potential to overcome resistance to, and enhance the performance of, cisplatin. We expect to continue advancing ONCONASE through the development process as we work to build a broad franchise in different therapeutic areas and via multiple treatment modalities."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alf
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 31, 2011 The Procter & Gamble Company (NYSE: ... joined its U.S. Sustainability Expert Advisory Panel (SEAP). The new ... Senior Manager, Clinton Global Initiative Dr. Howard Frumkin – ... Washington Terry Tamminen – Former Secretary, California Environmental Protection ...
... May 31, 2011 HeartSine Technologies, Inc, a ... its system warranty period to an exclusive 10 years on ... Public Access Defibrillator (PAD) for the ... currently is the fastest growing AED. The life of its ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3HeartSine® Increases AED System Warranty to Longest in the Industry 2
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... at the University of California, San Diego School of ... who have suffered a recent major loss are more ... adults. , The study is published in this month,s ... . , Because compassionate behaviors are associated with better ... offer insights into ways to improve the outcomes of ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... multinational corporation headquartered in Japan and the world,s ... of Toray Water Technology Laboratory (TWTL) in Singapore ... technologies. Nanyang Technological University (NTU),s Nanyang Environment and ... choice partner for its research activities in Singapore. ...
... Association (AUA) Foundation announced that Jennifer Dodson, MD, of ... AUA Foundation/NIDDK/NCI Surgeon-Scientist Award, offered by the AUA Foundation, ... Diseases (NIDDK) and the National Cancer Institute (NCI). ... have received the Surgeon-Scientist Award since the program began ...
... June 25, 2009, TIME: ... 722 12th St, NW, EVENT: ... town meeting to explain opposition to health care reform , ... on the 44th anniversary of Medicare., ...
... National Business Group on Health Recognizes HealthyQuest Program for ... 24 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that the National Business Group ... for Healthy Lifestyles Platinum Award to the company for ...
... CORTLANDT MANOR, N.Y., June 24 Polymedco, Inc. ... PATHFAST immunoassay analyzer, manufactured by Mitsubishi Chemical Medience ... of care system utilizes a chemiluminescent technology combined ... that allows this system to report highly accurate ...
... 2009) For Professor Chad Mirkin, good things come ... meter in size. Yet, as director of Northwestern University,s ... is anything but small. A prolific inventor and entrepreneur, ... of medical diagnostics and patient point-of-care and to ignite ...
Cached Medicine News:Health News:Toray to establish water treatment R&D center at NTU in Singapore 2Health News:Toray to establish water treatment R&D center at NTU in Singapore 3Health News:National Physician Summit & Petition: 'Take Back Medicine' 6/25/09 2Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 2Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 3Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 4Health News:Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles' 5Health News:PATHFAST(R) Rapid Whole Blood Immunoassay Analyzer from Polymedco 2Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 2Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 3Health News:World-renowned nanotechnology expert proves there is big potential in the smallest of matter 4
Baby Weitlaner retractor, blunt, 4"....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
15" overall length, 5" handle....
15" overall length, 9" handle....
Medicine Products: